WHO: “Protect yourself. Protect your family. Protect your community”: Bangladesh launches preventive cholera vaccination campaign.
Speech of the WHO Representative to Bangladesh, Dr Ahmed Jamsheed Mohamed, at the National Launch of the Preventive Oral Cholera Vaccination Campaign 2026, Nagar Bhaban Auditorium, Dhaka South City Corporation, Dhaka.
Published: August 20, 2026.
African Bundibugyo ebolavirus vaccine candidate to be advanced to clinical trials.
Leading African biopharmaceutical company Minapharm Group, headquartered in Egypt with subsidiaries in Berlin, will receive up to US$16.5 million from the Coalition for Epidemic Preparedness Innovations (CEPI) to advance the development of a Bundibugyo ebolavirus vaccine candidate, strengthening efforts to develop vaccines to combat the fastest-growing and second-largest Ebola outbreak on record affecting the Democratic Republic of the Congo (DRC).
Published: August 27, 2026.
https://cepi.net/african-bundibugyo-ebolavirus-vaccine-candidate-be-advanced-clinical-trials
GSK to advance mRNA seasonal flu vaccine candidate to phase III following positive phase II data.
GSK plc (LSE/NYSE: GSK) presented positive phase II data for its mRNA seasonal influenza (flu) vaccine candidate at the OPTIONS XIII Conference for the Control of Influenza. GSK’s vaccine candidate showed higher immune responses against all influenza strains tested compared to licensed standard dose and high dose inactivated flu vaccines in younger and older adults respectively and was generally well tolerated. Based on these results, GSK intends to start a phase III efficacy trial in September 2026.
Published: September 1, 2026.
IVI marks 25 years of its International Vaccinology Course with global training connecting Seoul, Kigali, and Stockholm.
The International Vaccine Institute (IVI) today opened its 25th International Vaccinology Course, marking a milestone for IVI’s flagship training program covering the full spectrum of vaccinology, from vaccine science and development to delivery and use. Established in 2000, it is now one of Asia’s longest-running courses of its kind and has since expanded into a global program connecting vaccine professionals across continents.
Published: August 31, 2026.
New design strategy expands nanoparticle vaccine approach to influenza viruses.
Scripps Research scientists develop a blueprint for stabilizing key influenza proteins and using them to make next-generation vaccine candidates. Influenza viruses are constantly evolving to escape recognition by the immune system. Much of this evolution involves hemagglutinin (HA), a key surface protein that enables the virus to attach to and enter human cells. Influenza can evade existing immunity through two major mechanisms: the gradual accumulation of mutations that alter HA and reduce immune recognition (antigenic drift), or more substantial genetic changes, including reassortment, that can generate novel viral characteristics and potentially contribute to pandemics (antigenic shift). Because circulating influenza viruses continue to evolve, seasonal vaccination remains the cornerstone of prevention, with vaccine composition regularly updated to provide the best possible match against the strains expected to predominate each season.Scientists at Scripps Research offer a blueprint for how to stabilize the various versions of influenza’s HA protein and use it to build nanoparticle vaccine candidates. Influenza is the latest target made compatible with the nanoparticle technology, specifically called self-assembling protein nanoparticles (SApNPs), which work by organizing many copies of viral proteins into clusters that the immune system can more easily recognize. This framework could eventually be applied to inform design of next-generation vaccines across diverse flu viruses.
Published: September 1, 2026.
Does the shingles vaccine cut heart-disease risk?
Mounting evidence suggests a link. Large study finds that people who received the ‘recombinant’ vaccine for the viral condition had a lower risk of cardiovascular problems.
Published: August 26, 2027.
https://www.nature.com/articles/d41586-026-02663-6
WHO revises Typhoid Vaccine Advice.
Amid rising antibiotic resistance, the World Health Organization mid rising antibiotic resistance, the World Health Organization (WHO) has updated its guidance on typhoid conjugate vaccine (TCV), recommending the first dose at 9-24 months in settings with high or very high typhoid incidence.
Published: September 1, 2026.
How a new global mpox vaccine stockpile could help the world respond faster to outbreaks.
The launch of a global mpox vaccine stockpile creates a long-term mechanism to ensure timely and equitable access to vaccines during outbreaks.
Published: September 3, 2026.
Over 1,000 Europeans infected by West Nile virus.
Europe has recorded 1,086 official cases of West Nile virus across 15 countries, according to the latest figures from the European Centre for Disease Prevention and Control.
Published: September 5, 2026.
https://www.brusselstimes.com/2303989/over-1000-europeans-infected-by-west-nile-virus
WHO validates Bhutan for eliminating dog-transmitted human rabies.
The World Health Organization (WHO) has validated Bhutan’s elimination of dog-transmitted rabies as a public health problem in the country. Bhutan is the first country in the WHO South-East Asia Region to achieve this success.
Published: September 4, 2026.
Ebola outbreak intelligence. Independent tracker — official WHO & ministry data, refreshed every 2 minutes. Map heat reflects reported case density.
As of September 9, 2026, there have been 5,798 confirmed cases with 2,786 deaths mostly in the Democratic Republic of Congo followed by Uganda.
Published: September 9, 2026.
European approval expands MenQuadfi meningococcal vaccination to infants from 6 weeks of age.
MenQuadfi has received an expanded European indication for immunization against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y, allowing vaccination to begin from 6 weeks of age.
Published: August 11, 2026.
The world has spent centuries forgetting the African history of immunization.
Historian Dr Elise Mitchell re-examines the early history of smallpox inoculation on both ends of the Atlantic slave trade.
Published: September 4, 2026.
https://www.gavi.org/vaccineswork/world-has-spent-centuries-forgetting-african-history-immunisation
A mosquito that can transmit Zika has bred in London – but that doesn’t mean the virus is spreading in people there.
The immediate risk is very low. The discovery shows how warmer weather may change Britain’s defences against mosquito-borne disease.
Published: September 7, 2026.
DRC’s Ebola outbreak has the potential to become a global pandemic. How to make sure it doesn’t.
Given its speed, scale and scope, the Bundibugyo Ebola virus disease that broke out in the Democratic Republic of Congo in mid-2026 could become a global epidemic.
Published: September 7, 2026.
Moderna cancer vaccine stops melanoma returning: what’s next for personalized treatments?
Promising trial results suggest cancer vaccines work and could be used to target other tumours. A personalized mRNA vaccine for melanoma reduced the risk of the cancer returning in a phase III clinical trial, the companies behind the trial announced this week. The vaccine — which relies on the same mRNA technology used to develop COVID-19 shots — is the first mRNA-based cancer treatment to show success in a late-stage trial.
Published: August 20, 2026.
https://www.nature.com/articles/d41586-026-02612-3
Why multidose-vaccine vials could be a game-changer for global RSV prevention.
WHO has given its stamp of approval to a multidose formulation of the maternal RSV vaccine for protecting infants.
Published: September 7, 2026.
Clover’s respiratory combo vaccines secure Phase II wins in elderly recipients.
The biotech says the mid-stage results for both of its combination respiratory vaccines support their continued development. In the multi-centre mid-stage study, which was conducted in Australia and recruited 420 adults aged between 60 and 85 years of age, Clover pitted the efficacy, safety and immunogenicity profile of two of its pipeline respiratory vaccines against a placebo. This includes SCB-1022 – a dual respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) shot – as well as SCB-1033, which Clover designed to protect against RSV, hMPV and Parainfluenza virus type 3 (PIV3).
Published: September 7, 2026.
Getting beyond awareness: ‘learning by doing’ to reach zero-dose children in India.
In Bihar and Uttar Pradesh, under-immunized urban communities are brought into a problem-solving process with a difference.
Published: September 2, 2026.
Zambia reports anthrax outbreak, Dozens of animals and people affected.
Authorities have recorded deaths of 46 hippopotamuses, 5 buffaloes, 1 crocodile and 8 elephants since July 2026. Approximately a dozen human cases with signs consistent with anthrax have been reported in Nabwalya. The cases are reportedly linked to the consumption of meat from animals found dead in the Munyamadzi River area.
Published: September 13, 2026.
https://outbreaknewstoday.substack.com/p/zambia-reports-anthrax-outbreak-dozens
PAHO: Chile becomes first country in South America validated for eliminating dog-transmitted rabies as a public health problem.
Chile has become the first country in South America to receive the World Health Organization (WHO) validation for eliminating dog-transmitted rabies as a public health problem. The recognition highlights more than 50 years of progress without a human case of rabies and confirms the country’s capacity to prevent transmission from re-emerging.
Published: September 14, 2026.
Asia on high alert as El Niño threatens new Dengue epidemic – The Telegraph.
Published: September 16, 2026.
New “blockbuster” tuberculosis vaccines could save seven million lives by 2050.
Next-generation TB vaccines, expected to become available from 2029, could deliver major health and economic gains, helping to save an estimated 7.3 million lives, generate up to US$ 135 billion in economic benefits for low-and middle-income countries by 2050, and support efforts to combat antimicrobial resistance. Action must be taken now to ensure that countries with the highest disease burden are able to access vaccines in sufficient quantities Gavi CEO, Dr Sania Nishtar: “Novel TB vaccines could be the next blockbuster immunization tool, however they will only realize their potential if we can ensure sufficient, predictable and affordable supply for those countries that need them most.”
Published: September 14, 2026.
Free Disease Outbreak Tracking Website.
The most comprehensive disease outbreak tracking website for 2026. Monitor 200+ diseases in real-time with AI-powered alerts, wastewater surveillance data, and global outbreak maps. Free access to the intelligence healthcare systems trust.
https://chatgpt.com/c/6aa39e92-3ab0-83e8-84b3-540d07d3e3b5
Ontario Celebrates Grand Opening of Sanofi’s Newest Biomanufacturing Facility.
Facility will strengthen province’s leadership in life sciences and create 300 highly skilled jobs
Published: September 16, 2026.
